KALA vs. NRBO, BIVI, COCP, SYBX, TCRT, INDP, LUMO, SLGL, ORGS, and AYTU
Should you be buying KALA BIO stock or one of its competitors? The main competitors of KALA BIO include NeuroBo Pharmaceuticals (NRBO), BioVie (BIVI), Cocrystal Pharma (COCP), Synlogic (SYBX), Alaunos Therapeutics (TCRT), Indaptus Therapeutics (INDP), Lumos Pharma (LUMO), Sol-Gel Technologies (SLGL), Orgenesis (ORGS), and Aytu BioPharma (AYTU). These companies are all part of the "pharmaceutical preparations" industry.
NeuroBo Pharmaceuticals (NASDAQ:NRBO) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking and earnings.
NeuroBo Pharmaceuticals presently has a consensus target price of $10.00, indicating a potential upside of 114.59%. KALA BIO has a consensus target price of $16.50, indicating a potential upside of 151.91%. Given NeuroBo Pharmaceuticals' higher probable upside, analysts clearly believe KALA BIO is more favorable than NeuroBo Pharmaceuticals.
NeuroBo Pharmaceuticals has higher earnings, but lower revenue than KALA BIO.
KALA BIO received 271 more outperform votes than NeuroBo Pharmaceuticals when rated by MarketBeat users. However, 75.00% of users gave NeuroBo Pharmaceuticals an outperform vote while only 66.67% of users gave KALA BIO an outperform vote.
NeuroBo Pharmaceuticals has a beta of -0.23, indicating that its stock price is 123% less volatile than the S&P 500. Comparatively, KALA BIO has a beta of -1.75, indicating that its stock price is 275% less volatile than the S&P 500.
1.4% of NeuroBo Pharmaceuticals shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 0.5% of NeuroBo Pharmaceuticals shares are owned by insiders. Comparatively, 13.4% of KALA BIO shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, KALA BIO had 3 more articles in the media than NeuroBo Pharmaceuticals. MarketBeat recorded 3 mentions for KALA BIO and 0 mentions for NeuroBo Pharmaceuticals. KALA BIO's average media sentiment score of 0.00 beat NeuroBo Pharmaceuticals' score of -0.40 indicating that NeuroBo Pharmaceuticals is being referred to more favorably in the media.
KALA BIO's return on equity of -90.22% beat NeuroBo Pharmaceuticals' return on equity.
Summary
KALA BIO beats NeuroBo Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
Get KALA BIO News Delivered to You Automatically
Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
KALA BIO Competitors List
Related Companies and Tools
